Offer document regarding EQL Pharma's offer to the shareholders of Sensidose Aktiebolag published

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to legislation, restrictions and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document which has been published in connection with this announcement and in connection with the beginning of the acceptance period for the Offer.

EQL Pharma AB (publ) ("EQL Pharma") announced on 20 April 2023 a public takeover offer to the shareholders of Sensidose Aktiebolag ("Sensidose") to transfer all shares in Sensidose for SEK 7.60 cash per share. The 24th of April EQL Pharma announced a revised offer, and unconditional, offer with a revised remuneration for the shares, SEK 8.40 (the “Offer”).  The offer document is available on EQL Pharma's website (www.eqlpharma.com) and Nordic Issuing's website (www.nordic-issuing.se). The acceptance period for the Offer begins tomorrow 25 April 2023 and ends on 16 May 2023 (subject to possible extension). Payment of consideration is expected to begin around 24 May 2023.

Information about the Offer

Information about the Offer is made available at www.eqlpharma.com.

Advisors

ABG Sundal Collier AB is financial advisor to EQL Pharma in connection with the Offer. Markets & Corporate Law Nordic AB is legal advisors to EQL Pharma in connection with the Offer and Nordic Issuing AB is issuing agent in connection with the Offer.

EQL Pharma AB (publ)

The board of directors